TNGX News and Press, Tango Therapeutics Inc.

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conferenc...

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESM...

2026-06-29 17:20:00 ET A week ago, I wrote that leadership had left the mega-cap “generals” and split into two baskets: semiconductors (velocity) and regional banks (breadth). That’s still true. But the dashboard has been quietly flagging a third group climbing the ...

2026-06-25 18:15:02 ET from Jefferies issued a price target of $60.00 for TNGX on 2026-06-25 20:07:42. The adjusted price target was set to $60.00. At the time of the announcement, TNGX was trading at $30.14. The overall price target consensus is at $42.70 with high pric...

2026-06-25 17:15:06 ET Raymond James analyst issues HOLD recommendation for TNGX on June 25, 2026 08:03PM ET. TNGX was trading at $30.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 11 - Buy, 2 - Hold ...

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azel...

2026-06-22 09:32:26 ET More on biotech stocks XBI: A "Hidden" ETF Up +70% In 1 Year. IBB: Space Stocks And AI Stealing The Risk-On Show In 2026 Biotech Is Holding Steady In 2026 Syntax Bio expands Series A to $14.4M, adds leadership and board members ...

2026-06-10 03:06:29 ET More on Tango Therapeutics Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancre...

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 1...

2026-06-09 15:10:32 ET Investment Overview I shared my first bullish take on Tango Therapeutics, Inc. ( TNGX ) with Seeking Alpha readers back in January 2024 , and the stock is up nearly 150% since. In subsequent notes in September 2024 and January 2025 , I also gav...